AVID BIOSERVICES INC. - COMMON STOCK

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments

08 9 2021 15:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices to Participate at Upcoming Investor Conferences

02 9 2021 15:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2022 After Market Close on September 8, 2021

01 9 2021 15:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors

01 7 2021 07:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments

29 6 2021 15:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021

22 6 2021 15:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)

25 5 2021 07:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock

15 4 2021 15:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

17 3 2021 07:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes

09 3 2021 23:20:03 提供 Nasdaq GlobeNewswire

Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes

08 3 2021 16:01:00 提供 Nasdaq GlobeNewswire

Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

03 3 2021 15:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021

01 3 2021 15:05:00 提供 Nasdaq GlobeNewswire

Avid Bioservices Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan

22 2 2021 07:05:00 提供 Nasdaq GlobeNewswire

Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

03 2 2021 06:00:00 提供 Nasdaq GlobeNewswire